Navigation Links
PARI Respiratory Equipment Offers New Respiratory Management Course
Date:11/12/2009

MIDLOTHIAN, Va., Nov. 12 /PRNewswire/ -- Today, PARI Respiratory Equipment launched a newly updated continuing education class, Managing Respiratory Patients Through Efficient Aerosol Delivery, rounding out their free learning program with seven classes for respiratory therapists, nurses, case managers, and pharmacists. The updated class allows participants to self-study online, enabling easier access for caregivers to update their skills and receive necessary credits for maintaining licensing. The rest of PARI's classes are designed as group programs and all are pre-approved for continuing education units by the Commission for Case Manager Certification (CCMC), American Association of Respiratory Care (AARC), Florida State Board of Nursing, and the California State Board of Nursing.

"As more people are diagnosed with respiratory illnesses and require treatment, it is imperative that clinicians keep up with changing technologies and devices that deliver inhaled medications. PARI's updated course, Managing Respiratory Patients Through Efficient Aerosol Delivery, is a comprehensive program providing free information on the differences between nebulizers, metered dose inhalers, and dry powder inhalers. Understanding how the interactions of patient, delivery device, and drug formulation influence drug delivery is crucial for respiratory clinicians," said Lisa Cambridge, director of Clinical Development at PARI Respiratory Equipment.

PARI Respiratory's continuing education classes can be accessed online at www.PARI.com/CEU and include:

  • Managing Respiratory Patients Through Efficient Aerosol Delivery
  • Managing the Patient with Asthma
  • Respiratory Management of Patients with Cystic Fibrosis
  • Case Management and COPD
  • Managing Childhood Asthma
  • Respiratory Drug Update
  • Challenges of the Chronic Respiratory Patient

About PARI Respiratory Equipment, Inc.

PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them.

Maker of the world's leading breath-enhanced reusable nebulizer, the PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufactures the award winning PARI TREK S compact compressor, Bubbles the Fish II aerosol mask, and durable PARI PRONEB Ultra II. PARI's Vortex anti-static valved holding chamber improves the aerosol deposition of metered dose inhalers (MDIs). PARI's North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at www.Pari.com

SOURCE PARI Respiratory Equipment, Inc.


'/>"/>
SOURCE PARI Respiratory Equipment, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
4. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
5. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
6. Fire Season: Respiratory Health a Concern
7. Alpha-1 Foundation President to Give Keynote Address at 53rd Annual Respiratory Congress of the AARC Foundation and Activities
8. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
9. Recently discovered virus associated with pediatric respiratory tract infection in Germany
10. New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory Depressant Effects in Patients With Moderate-to-Severe COPD
11. Kids Respiratory Virus Season Off and Running
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... CT (PRWEB) , ... March 28, 2017 , ... ... devices, announces today that the University of Pittsburgh Medical Center (UPMC) will acquire ... and Western Pennsylvania. , The program, developed in association with efforts by the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the ... results and maintaining GMP and USP compliance. In a new webinar from METTLER ... requirements " these requirements are explained. The challenge is to determine how ...
(Date:3/28/2017)... ... March 28, 2017 , ... With less than 10,000 dermatologists in the ... care can be limited while the desire to conquer breakouts and eliminate skincare stress ... for every customer online, today released its inaugural survey on the State of Acne ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of Juvly ... professionals in the country to sit on the 2017 National Advisory Board for Allergan’s ... years Dr. Harper helped propel the clinic from a small start-up to number 78 ...
(Date:3/28/2017)... PA (PRWEB) , ... March 28, 2017 , ... Public ... and across a variety of business channels. , While many results are clear, ... any public relations program. , When it comes to measurement, firms should always ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a ... commercialization of innovative therapies for the treatment of ... Agency (EMA) has notified the company that the ... Application (MAA) has passed validation, and that the ... MAA for ARX-04 (known as DSUVIA™ in the ...
(Date:3/28/2017)... MARLBOROUGH, Mass. , March 28, 2017 /PRNewswire/ ... RNAi company developing innovative therapeutics that address significant ... granted a patent from the Japan Patent Office ... targeting connective tissue growth factor (CTGF) for the ... not limited to skin fibrosis and proliferative retinopathy ...
(Date:3/28/2017)... 28, 2017 The global ... 8.0 billion by 2025, according to a new study ... infectious diseases and cancer is expected to upsurge the ... over the coming years. In addition, higher number of ... allogenic stem cell therapy, due to adverse effects caused ...
Breaking Medicine Technology: